Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits.
Vanna Geromel, Niklas Darin, Dominique Chrétien, Paule Bénit, Pascale DeLonlay, Agnès Rötig, Arnold Munnich, Pierre Rustin
Index: Mol. Genet. Metab. 77(1-2) , 21-30, (2002)
Full Text: HTML
Abstract
While there have been major advances in both the identification of the molecular basis and our understanding of mitochondrial pathology, the clinical management of patients with mitochondrial respiratory chain disease is still essentially supportive. Quinones are the only pharmacological agents that have proven some efficacy when, and only when, given to patients presenting with quite specific respiratory chain defects. In this article, after a short presentation of the coenzyme Q(10) molecule, its origin and distribution in human body, we summarize our present knowledge on its several physiological functions. We next discuss the rational that justifies using different types of quinones in the therapy of mitochondrial disorders. We finally briefly review the available data obtained in the therapy of mitochondrial disorders by using quinones as either substitutive electron carriers or antioxidant compounds.
Related Compounds
Related Articles:
2-deoxy-D-glucose enhances anesthetic effects in mice.
2015-02-01
[Anesth. Analg. 120(2) , 312-9, (2015)]
1994-08-01
[Drugs Aging 5(2) , 133-52, (1994)]
Idebenone: an emerging therapy for Friedreich ataxia.
2009-03-01
[J. Neurol. 256 Suppl 1 , 25-30, (2009)]
Pharmacokinetic evaluation of idebenone.
2010-11-01
[Expert Opin. Drug Metab. Toxicol. 6(11) , 1437-44, (2010)]
[The use of idebenone (noben) in neurological practice].
2006-01-01
[Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 106(11) , 66-71, (2006)]